Unlock instant, AI-driven research and patent intelligence for your innovation.

Crystal form of eb-1020 and its preparation method and use

A crystal form and application technology, applied in the field of medicinal chemistry, can solve the problems of poor stability of crystal form C, difficult purification of crystal form B, poor compressibility and fluidity of needle-like crystals, and improve hardness/friability. , reduce costs and improve product quality

Active Publication Date: 2022-03-25
CRYSTAL PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to paragraph [00232] of the specification of WO2016205762A, the crystal form C transforms into a mixture of crystal forms A and B after two weeks at 40°C / 75% relative humidity, and the inventors found that the existing crystal form C was placed at room temperature After one month, it will be transformed into Form A. It can be seen that the existing Form C has poor stability and the risk of drug development is high.
[0006] Section [00172] of WO2016205762A description records that there is a diffraction peak of A in the XRPD pattern of crystal form B, indicating that crystal form A is easily mixed in crystal form B. It can be seen that crystal form B is difficult to purify, which is not conducive to large-scale production and in preparations. Applications
According to paragraph [00179] of the specification of WO2016205762A, it can be known that the existing crystal forms A and B are needle-shaped crystals, and the compressibility and fluidity of the needle-shaped crystals are poor, which is not conducive to preparation tableting, and the needle-shaped crystals are usually easily charged with static electricity, and the preparation molding is relatively difficult. difficulty

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystal form of eb-1020 and its preparation method and use
  • Crystal form of eb-1020 and its preparation method and use
  • Crystal form of eb-1020 and its preparation method and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0115] Example 1: Preparation of crystal form CS1

[0116] Weigh about 15 mg of compound (I) raw material, place it in DSC, heat it to 248°C at a speed of 10°C / min to melt, then cool to room temperature to obtain a white solid.

[0117] After testing, the obtained solid is the crystal form CS1 of the present invention, and its X-ray powder diffraction data are as follows: figure 1 , shown in Table 1.

[0118] 1 HNMR such as figure 2 As shown, the NMR data are: 1 HNMR{(400MHz,d 6 -DMSO) δ 9.73 (s, 2H), 7.86 (dd, J=18.0, 12.1Hz, 4H), 7.53-7.43 (m, 2H), 7.38 (dd, J=8.6, 1.2Hz, 1H), 3.77 (d, J=11.1Hz, 1H), 3.64-3.49(m, 2H), 3.42(d, J=11.2Hz, 1H), 2.24(dt, J=8.3, 4.2Hz, 1H), 1.48(t, J=5.3Hz, 1H), 1.28-1.15(m, 1H).}

[0119] The DSC of crystal form CS1 obtained in this embodiment is as follows: image 3 As shown, an endothermic peak begins to appear when heated to around 247°C, which is the melting endothermic peak of crystal form CS1.

[0120] The TGA of crystal form CS...

Embodiment 2

[0127] Example 2: Stability of Form CS1

[0128] Weigh the crystal form CS1 of the present invention, place it in the open for 6 weeks under the conditions of 25°C / 60% relative humidity and 40°C / 75% relative humidity, and place it in the open for 1 week under the condition of 80°C, and measure it by HPLC and XRPD The changes of crystal form and chemical purity are shown in Table 3 and Table 4.

[0129] table 3

[0130]

[0131]

[0132] Table 4

[0133] placement conditions Purity after standing for 1 week Purity after 2 weeks Purity after 6 weeks 25℃ / 60% relative humidity 99.93% 99.95% 99.94% 40℃ / 75% relative humidity 99.95% 99.95% 99.97% 80℃ 99.82% —— ——

[0134] The results show that the crystal form CS1 can be stable for at least 6 weeks under the conditions of 25°C / 60% relative humidity and 40°C / 75% relative humidity, and it can be stable for at least 1 week under the harsh conditions of 80°C. The chemical purity of CS...

Embodiment 3

[0135] Example 3: Comparison of grinding stability of crystal form CS1, existing crystal form A and crystal form B

[0136] Take the crystal form CS1 of the present invention, the existing crystal form A and the crystal form B respectively and place them in a mortar, and grind them manually for 5 minutes. The XRPD patterns of the crystal form CS1 of the present invention before and after grinding are as follows Figure 8 As shown (the picture above is before grinding, and the picture below is after grinding), the XRPD patterns of the existing crystal form A before and after grinding are as follows Figure 9 As shown (the picture above is before grinding, and the picture below is after grinding), the XRPD pictures of the existing crystal form B before and after grinding are as follows Figure 10 As shown (the picture above is before grinding, and the picture below is after grinding).

[0137] The results show that the crystal form CS1 of the present invention does not change...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
diameteraaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a crystal form of compound (I) and a preparation method thereof, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of triple reuptake inhibitors of 5-serotonin, norepinephrine and dopamine and / or in the treatment of neuropathy Use in pharmaceutical preparations for systemic disorders. The crystal form of compound (I) provided by the present invention has one or more improved properties compared with the prior art, and is of great value to the optimization and development of the drug in the future.

Description

technical field [0001] The present invention relates to the field of medicinal chemistry. Specifically, it relates to the crystal form of EB-1020 and its preparation method and use. Background technique [0002] Norepinephrine, serotonin, and dopamine are three biogenic amines associated with various neurological disorders, and inhibition of their reuptake could potentially treat central nervous system disorders. EB-1020 (Centanafadine Hydrochloride) is a triple reuptake inhibitor (TRI) that inhibits the reuptake of norepinephrine, serotonin and dopamine. Studies have shown that EB-1020 has potential palliative or therapeutic effects on neurological disorders, especially attention deficit hyperactivity disorder (ADHD). [0003] The chemical name of EB-1020 is: (1R,5S)-1-(naphthalene-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride (hereinafter referred to as "compound (I)" ), its structural formula is as follows: [0004] [0005] The prior art WO2016205762A discloses cr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D209/52A61K31/403A61K45/06
CPCA61K31/403A61K45/06C07D209/52C07B2200/13
Inventor 陈敏华张炎锋翟晓婷张晓宇
Owner CRYSTAL PHARMA CO LTD